Exelixis (EXEL) Q2 2026: Zanza Franchise Pipeline Expands Across 7 Pivotal Trials, Guidance Trimmed
Exelixis advanced its multi-franchise oncology strategy with Zanza now spanning seven pivotal trials, but leadership trimmed 2026 guidance as the NET indication ramps more gradually than expected. Management is executing on commercial gains in RCC and NET, while accelerating launch readiness for Zanza in third-line colorectal cancer and deepening its R&D pipeline. Disciplined capital allocation, including $312 million in share repurchases, underscores a focus on long-term value as the company navigates evolving market dynamics and pipeline milestones.
Summary
- Zanza Franchise Buildout: Seven pivotal trials position Zanza as Exelixis’ next major oncology growth engine.
- Commercial Execution: CaboMedix gains share in RCC and NET, but NET patient ramp is slower than planned.
- Guidance Reset: Updated 2026 outlook reflects a more measured NET uptake and disciplined expense management.
Business Overview
Exelixis is an oncology-focused biopharmaceutical company, generating revenue primarily through sales of its lead tyrosine kinase inhibitor (TKI), Cabozantinib (Cabo), marketed as CaboMedix in the U.S., and through royalties from international partners. The business is structured around two core franchises: the established Cabo franchise, which leads in renal cell carcinoma (RCC) and neuroendocrine tumors (NET), and the emerging Zanza (zanzalitinib) franchise, which is advancing through pivotal trials across multiple tumor types. Exelixis also invests in a pipeline of early-stage oncology candidates and leverages commercial partnerships to extend its reach globally.
Performance Analysis
Exelixis delivered total revenues of $629 million in Q2 2026, with the Cabo franchise contributing $573 million in net product sales, reflecting a 10% year-over-year increase. The franchise remains the market leader in RCC, capturing over 45% new patient share in the second-line-plus oral TKI segment, and is extending its reach in the NET indication, albeit with a slower ramp due to patient kinetics in this heterogeneous, slower-growing tumor type. International royalties from partners Ipsen and Takeda added $53 million, underscoring the global relevance of the Cabo platform.
Gross-to-net deductions for Cabo decreased to 29.5%, driven by lower copay assistance, offset by higher 340B utilization. Operating expenses rose sequentially to $380 million, largely from increased clinical trial and marketing spend, as well as higher stock-based compensation. Notably, Exelixis repurchased $312 million in stock, completing a prior buyback program and leaving $598 million under a new authorization. Management lowered and narrowed 2026 revenue and R&D guidance, citing a more gradual NET ramp, but emphasized continued investment in pipeline and launch readiness for Zanza.
- RCC Franchise Momentum: CaboMedix grew new patient market share to 47%, outpacing the broader TKI market’s growth rate.
- NET Uptake Slower: NET patient initiation lags due to indolent disease kinetics, impacting near-term revenue trajectory.
- Capital Return: Share repurchases signal confidence in long-term value despite near-term commercial headwinds.
Overall, Exelixis remains financially robust, with $1.4 billion in cash and marketable securities, providing ample runway to support both commercial execution and pipeline expansion.
Executive Commentary
"Zanza is leading the pack as our next potential franchise opportunity and our highest R&D priority. The Exelixis team continues to execute on key objectives across the program, including pivotal trial data readouts, expediting clinical trial enrollments, and new study initiations."
Michael M. Miller, President and Chief Executive Officer
"We are lowering and narrowing our total revenues and net product revenue guidance, which lowers the midpoint by $50 million when compared to our previous guidance. This updated financial guidance reflects modestly slower growth in 2026 due to a more gradual ramp for the NET indication than the original projections."
Chris Cabrera, Senior Vice President and Chief Financial Officer
Strategic Positioning
1. Zanza Franchise Acceleration
Zanza (zanzalitinib), Exelixis’ next-generation TKI, is the centerpiece of the company’s future growth strategy. With seven pivotal trials either ongoing or imminent—including STELLAR-303 in colorectal cancer (CRC), STELLAR-304 in non-clear cell RCC, and STELLAR-311 in NET—Zanza is being positioned as a multi-indication franchise. Launch readiness for Zanza in third-line-plus CRC is a top priority, with commercial teams mobilized ahead of the PDUFA date in December.
2. Cabo Franchise Optimization
CaboMedix remains the leading oral TKI in RCC and is gaining share in NET, supported by expanded GI sales teams and refined targeting through granular utilization data. Leadership continues to focus on maximizing market penetration, especially in community oncology settings, and leveraging refill dynamics as patient share increases.
3. Pipeline Breadth and Modality Expansion
Exelixis is broadening its R&D pipeline with early-stage assets (XL309, XB010, XB628, XB371) and new small molecule and ADC (antibody-drug conjugate) programs. The company is also exploring Zanza combinations with immunotherapies and other modalities, seeking to establish new standards of care in underserved tumor types.
4. Capital Allocation and Expense Discipline
Disciplined capital deployment is evident through substantial share repurchases and a reduction in R&D expense guidance. This approach aims to balance investment in pipeline innovation with shareholder returns, while maintaining strategic flexibility to respond to evolving market and regulatory conditions.
5. Global Commercial Strategy
Exelixis continues to evaluate partnership opportunities for Zanza ex-U.S., mirroring the successful Cabo model. Management is weighing all options to optimize global reach and value creation, with interest expected to increase as pivotal trial data matures.
Key Considerations
This quarter signals a pivotal transition as Exelixis shifts from a single-product to a multi-franchise oncology company, with Zanza’s pipeline breadth and commercial launch preparation at the forefront. While the Cabo franchise continues to deliver, the company’s long-term trajectory hinges on successful Zanza execution and regulatory milestones.
Key Considerations:
- Pipeline Execution Pace: Timely enrollment and data readouts across seven Zanza pivotal trials are critical for franchise momentum.
- Commercial Uptake Dynamics: NET patient ramp is slower than modeled, affecting near-term sales, but refill growth and share gains remain positive signals.
- Regulatory Milestones: The upcoming PDUFA decision for Zanza in CRC could unlock a $1.5 billion opportunity if label breadth is favorable.
- Expense and Capital Allocation: Lowered R&D spend and ongoing buybacks reflect management’s commitment to balancing growth and shareholder value.
- Competitive Landscape: Evolving standards in RCC and CRC, as well as the emergence of new modalities, require agile strategic adaptation.
Risks
Exelixis faces execution risk on Zanza’s pivotal trials, including potential delays in enrollment or regulatory review, and the possibility of less favorable label outcomes in key indications. Competitive threats from new therapies in RCC, NET, and CRC, as well as generic erosion post-2031, add uncertainty to long-term revenue durability. Expense discipline must be balanced against the need to invest in commercial and R&D infrastructure to support franchise expansion.
Forward Outlook
For Q3 2026, Exelixis guided to:
- Continued Cabo franchise growth, with focus on RCC and NET share gains
- Ongoing preparation for potential Zanza CRC launch pending regulatory approval
For full-year 2026, management narrowed revenue guidance, lowering the midpoint by $50 million, and reduced R&D expense midpoint by the same amount. Key factors highlighted include:
- More gradual NET patient ramp due to disease kinetics and trial enrollment overlap
- Disciplined expense management to maintain capital flexibility
Takeaways
Exelixis is at a strategic inflection, leveraging Cabo’s commercial durability to fund Zanza’s multi-indication buildout and pipeline expansion. The company’s ability to convert pivotal trial momentum into regulatory and commercial wins will define its next phase.
- Franchise Diversification: Zanza’s seven pivotal trials set the stage for a broader, more resilient growth platform beyond Cabo.
- Commercial Execution: Share gains in RCC and NET offset some near-term softness from slower NET ramp, with GI team expansion supporting future launches.
- Pipeline Readouts: Investors should watch for regulatory decisions and trial data, especially in CRC and RCC, as key value inflection points in the next 6-12 months.
Conclusion
Exelixis is methodically transitioning from a single-product leader to a multi-franchise oncology innovator, with Zanza positioned to drive the next wave of growth. Disciplined financial management and robust pipeline execution will be vital to capitalizing on upcoming regulatory and commercial milestones.
Industry Read-Through
Exelixis’ pipeline breadth and launch readiness for Zanza highlight the increasing importance of multi-indication franchises in oncology, as companies seek to diversify risk and capture larger addressable markets. The slower-than-expected NET uptake underscores the complexity of launching in heterogeneous, indolent tumor types, with patient kinetics and trial overlap affecting revenue timing. Capital discipline and aggressive share repurchases are becoming more prevalent as biopharma companies balance pipeline investment with shareholder returns. Competitors in RCC, CRC, and NET should note the emphasis on combination regimens and the need to differentiate through both clinical data and commercial execution.